The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Testosterone (Testavan®) has been accepted for restricted use as testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. The restriction limits use to patients requiring a transdermal delivery system and it is noted that this product is bioequivalent to another testosterone transdermal preparation and costs less.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Updates - March 2019||Drug Safety Update - April 2019 »|